Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2024 03:00 ET | Source: Immodulon

Precision-Panc Team Open the PRIMUS-006 Study, a Novel Combination of IMM-101, Gemcitabine and Pembrolizumab

– PRIMUS-006 study led by Professors David Chang and Jeff Evans of the University of Glasgow –– Phase II study is evaluating a novel combination in first-line metastatic pancreatic cancer – GLASGOW,...
April 29, 2024 08:00 ET | Source: Immodulon

Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium

UXBRIDGE, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of...
December 11, 2023 12:00 ET | Source: Immodulon

Immodulon Announces Formation of New Scientific Advisory Board to Support Late-stage Clinical Development of IMM-101

– Professor Dr. med. Thomas Seufferlein appointed Chair of new Scientific Advisory Board (SAB) composed of leaders with deep expertise in the clinical oncology field – – New SAB to complement...
June 26, 2023 03:00 ET | Source: Immodulon

Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer

Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer Richard Couch, formerly at Celgene,...
June 05, 2023 07:00 ET | Source: Immodulon

Immodulon Appoints Experienced Clinical and Medical Affairs Executive Josefine Roemmler-Zehrer, MD, Associate Professor, as Chief Medical Officer

Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertiseAdding further oncology experience to Immodulon’s leadership team as...
May 10, 2023 03:00 ET | Source: Immodulon

Immodulon Appoints New Chair and Leadership Team to Drive Late-Stage Clinical Development of IMM-101 in Pancreatic Cancer

Richard Davies, Deputy Chairman of Alvotech, elected as Chairman of the BoardGertjan Bartlema, formerly at Celgene and Amgen, appointed as Chief Executive OfficerPeter Greaney, formerly at ADC...